Medline (MDLN) Common Equity (2024 - 2026)

Medline (MDLN) has reported Common Equity for 3 consecutive years, with $19.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to $19.1 billion in Q2 2026; TTM through Jun 2026 was $19.1 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $19.3 billion, up 19.36% from the prior year.
• Common Equity was $19.1 billion for Q2 2026 at Medline, down from $19.3 billion in the prior quarter.
• Over five years, Common Equity peaked at $19.3 billion in Q1 2026 and troughed at $16.2 billion in Q4 2024.
• A 3-year average of $18.5 billion and a median of $19.2 billion in 2025 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 19.36% in 2025, down 19.36% in 2025.
• Over 3 years, Common Equity stood at $16.2 billion in 2024, then advanced by 19.36% to $19.3 billion in 2025, then decreased by 1.08% to $19.1 billion in 2026.
• The last three Common Equity figures came in at $19.1 billion (Q2 2026), $19.3 billion (Q1 2026), and $19.3 billion (Q4 2025), per Business Quant data.